B-Cell Maturation Antigen

The FDA granted orphan drug designation to ALLO-715 for the treatment of advanced multiple myeloma, according to the agent’s manufacturer.

Subcutaneous elranatamab demonstrated efficacy and a manageable safety profile in patients with relapsed or refractory multiple myeloma, according to data presented at the virtual ASCO Annual Meeting.

The FDA granted fast track designation to ALLO-605, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory multiple myeloma.

More than 80% of patients with relapsed or refractory multiple myeloma remained alive 18 months after receiving a single infusion of ciltacabtagene autoleucel, according to the latest results of a phase 1/phase 2 clinical trial.

Teclistamab showed encouraging efficacy among patients with relapsed or refractory multiple myeloma, according to results of the phase 1 MajesTEC-1 study presented during the virtual ASCO Annual Meeting.

A novel chimeric antigen receptor T-cell therapy induced responses in the first 12 evaluable patients with relapsed or refractory multiple myeloma treated in a phase 1 dose-escalation trial.

The FDA cleared an investigational new drug application for ALLO-605, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory multiple myeloma, according to the agent’s manufacturer.

The FDA granted regenerative medicine advanced therapy designation to ALLO-715, an allogeneic chimeric antigen receptor T-cell therapy for adults with relapsed or refractory multiple myeloma, according to the manufacturer.

Although it took a bit longer than expected, the first FDA approval of a chimeric antigen receptor T-cell therapy for advanced multiple myeloma will have a major impact on clinical practice, according to experts.

Chimeric antigen receptor T-cell therapies demonstrated greater clinical effectiveness than standard care among patients with heavily pretreated multiple myeloma, according to a report by the Institute for Clinical and Economic Review.